01 February 2021

Amedeo Smart

Independent Medical Education


Subscriber: th..@boehringer-ingelheim.com

HIV Infection

01 February 2021 | n=41

  1. .
    A multilevel intervention to reduce stigma among alcohol consuming men living with HIV receiving antiretroviral therapy: findings from a randomized control trial in India: Erratum.
    AIDS 2021;35:527.

  2. Luo G, Su L, Hu X, Lin YF, et al.
    The role of e-commerce platforms in optimizing the HIV care continuum.
    AIDS 2021;35:521-522.

  3. Vance DE, Brew BJ.
    HIV neurocognitive impairment and Alzheimer's disease: sniffing out the difference.
    AIDS 2021;35:511-513.

  4. Nyakato P, Schomaker M, Sipambo N, Technau KG, et al.
    Virologic response of adolescents living with perinatally acquired HIV receiving antiretroviral therapy in the period of early adolescence (10-14 years) in South Africa.
    AIDS 2021.

  5. Lapadula G, Bernasconi DP, Bai F, Foca E, et al.
    Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances: Results from a randomized controlled trial.
    AIDS 2019.

  6. Chawana TD, Nhachi CFB, Nathoo K, Ngara B, et al.
    Higher tenofovir concentrations in hair are associated with decreases in viral load and not self-reported adherence in HIV-infected adolescents with second line virological treatment failure.
    AIDS Res Hum Retroviruses 2021.

  7. Devanathan AS, Kashuba A.
    HIV Persistence in the Spleen: Opportunities for Pharmacologic Intervention.
    AIDS Res Hum Retroviruses 2021.

  8. Hariyanto TI, Putri C, Frinka P, Louisa J, et al.
    Human Immunodeficiency Virus (HIV) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A Meta-Analysis and Meta-Regression.
    AIDS Res Hum Retroviruses 2021.

  9. Galiwango RM, Ssuuna C, Kaleebu P, Kigozi G, et al.
    Validation of the Asante HIV-1 Rapid Recency(R) Assay for detection of recent HIV-1 infections in Uganda.
    AIDS Res Hum Retroviruses 2021.

  10. Di Carlo D, Falasca F, Palermo E, Mezzaroma I, et al.
    Dolutegravir-based regimen for maintenance of viral suppression in people living with HIV: 48-week results in real life setting.
    AIDS Res Hum Retroviruses 2021.

  11. Barbee LA, Soge OO, Khosropour CM, Haglund M, et al.
    The Duration of Pharyngeal Gonorrhea: A Natural History Study.
    Clin Infect Dis 2021.

  12. Fung M, Babik JM.
    COVID-19 in Immunocompromised Hosts: What We Know So Far.
    Clin Infect Dis 2021;72:340-350.

  13. Manion M, Lynn N, Pei L, Hammoud DA, et al.
    To Induce Immune Reconstitution Inflammatory Syndrome or Suppress It: The Spectrum of Mycobacterium genavense in the Antiretroviral Era.
    Clin Infect Dis 2021;72:315-318.

  14. Dong HV, Adamson PC, Nguyen HT, Nguyen TV, et al.
    Reply to Laumen et al.
    Clin Infect Dis 2021;72:364-365.

  15. Nachega JB, Grimwood A, Mahomed H, Fatti G, et al.
    From Easing Lockdowns to Scaling Up Community-based Coronavirus Disease 2019 Screening, Testing, and Contact Tracing in Africa-Shared Approaches, Innovations, and Challenges to Minimize Morbidity and Mortality.
    Clin Infect Dis 2021;72:327-331.

  16. Liu L, Wang L, Zhang H, Ou W, et al.
    Changing Epidemiology of HBV and HCV Co-Infection in HIV-Positive Population in China: Results from the Third and Fourth Nationwide Molecular Epidemiologic Surveys.
    Clin Infect Dis 2021.

  17. Kirkegaard-Klitbo DM, Thomsen MT, Gelpi M, Bendtsen F, et al.
    Hepatic steatosis associated with exposure to elvitegravir and raltegravir.
    Clin Infect Dis 2021.

  18. Anugwom CM, Aby ES, Debes JD.
    Inverse association between chronic hepatitis B infection and COVID-19: immune-exhaustion or coincidence?
    Clin Infect Dis 2020.

  19. van der Graaf R, Reis A, Godfrey-Faussett P.
    Revised UNAIDS/WHO Ethical Guidance for HIV Prevention Trials.
    JAMA 2021.

  20. Slomski A.
    Simplified Regimen Expands Options for Dual-Therapy HIV Maintenance.
    JAMA 2021;325:334.

  21. Weng MK, Harris AM, Nelson NP.
    Update on Hepatitis A Management.
    JAMA 2021;325:401.

  22. Tien-Huan L, Ismael FC, Suzue S, Rommel B, et al.
    Evaluating Nonresponse Weighting Adjustment for the Population-Based HIV Impact Assessments Surveys: On Incorporating Survey Outcomes.
    J Acquir Immune Defic Syndr 2021.

  23. Johnson KA, Chen MJ, Kohn R, Sachdev D, et al.
    Acute HIV at the time of initiation of Pre or Post Exposure Prophylaxis: Impact on drug-resistance and clinical outcomes.
    J Acquir Immune Defic Syndr 2021.

  24. Pampati S, Emrick K, Siegler AJ, Jones J, et al.
    Changes in sexual behavior, PrEP adherence, and access to sexual health services due to the COVID-19 pandemic among a cohort of PrEP-using MSM in the South.
    J Acquir Immune Defic Syndr 2021.

  25. Busza J, Hensen B, Birdthistle I, Chabata ST, et al.
    What's in a name? A mixed method study on how young women who sell sex characterise male partners and their use of condoms.
    J Acquir Immune Defic Syndr 2021.

  26. Ongolly FK, Dolla A, Ngure K, Irungu EM, et al.
    "I just decided to stop: " Understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya.
    J Acquir Immune Defic Syndr 2021.

  27. Coburn SB, Shiels M, Silverberg M, Horberg M, et al.
    Secular Trends in Breast Cancer Risk among Women with HIV Initiating ART in North America.
    J Acquir Immune Defic Syndr 2021.

  28. Zhang L, Abohashem S, Osborne MT, Naddaf N, et al.
    Lower Socioeconomic Status Associates with Greater Systemic and Arterial Inflammation in HIV.
    J Acquir Immune Defic Syndr 2021.

  29. Crable EL, Blue TR, McKenzie M, Rich JD, et al.
    Effect of case management on HIV outcomes for community corrections population: Results of an 18-month randomized controlled trial.
    J Acquir Immune Defic Syndr 2021.

  30. Muccini C, Galli L, Poli A, Chiurlo M, et al.
    Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression who switched to a different antiretroviral regimen.
    J Acquir Immune Defic Syndr 2021.

  31. Chen Y, Gao Y, Zhou Y, Li X, et al.
    Human Immunodeficiency Virus Infection and Incident Heart Failure: A Meta-analysis of Prospective Studies.
    J Acquir Immune Defic Syndr 2021.

  32. Goodrich S, Siika A, Mwangi A, Nyambura M, et al.
    Development, assessment and outcomes of a community-based model of anti-retroviral care in western Kenya through a cluster-randomized control trial.
    J Acquir Immune Defic Syndr 2021.

  33. van der Heijden WA, Wan J, Van de Wijer L, Jaeger M, et al.
    Plasmatic coagulation capacity correlates with inflammation and abacavir-use during chronic HIV-infection.
    J Acquir Immune Defic Syndr 2021.

  34. Jenness SM, Le Guillou A, Chandra C, Mann LM, et al.
    Projected HIV and Bacterial STI Incidence Following COVID-Related Sexual Distancing and Clinical Service Interruption.
    J Infect Dis 2021.

  35. Eaton EF, Clement ME.
    Wave the Yellow Flag: Why we should prioritize routine HIV and STI care now.
    J Infect Dis 2021.

  36. Nasreddine R, Florence E, Moutschen M, Yombi JC, et al.
    Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.
    J Med Virol 2021.

  37. Matsui H, Shirakawa K, Konishi Y, Hirabayashi S, et al.
    CAGE-seq reveals that HIV-1 latent infection does not trigger unique cellular responses in a Jurkat T cell model.
    J Virol 2021.

  38. Janaka SK, Palumbo AV, Tavakoli-Tameh A, Evans DT, et al.
    Selective Disruption of SERINC5 Antagonism by Nef Impairs SIV Replication in Primary CD4(+) T Cells.
    J Virol 2021.

  39. Pusnik J, Fischinger S, Dittmer U, Esser S, et al.
    Production of HIV-1 Env-specific antibodies mediating innate immune functions depends on cognate IL-21- secreting CD4+ T cells.
    J Virol 2021.

  40. Singh NS, Ataullahjan A, Ndiaye K, Das JK, et al.
    Delivering health interventions to women, children, and adolescents in conflict settings: what have we learned from ten country case studies?
    Lancet 2021.

  41. Rappazzo CG, Tse LV, Kaku CI, Wrapp D, et al.
    Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
    Science 2021.


Display articles in


Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:



Amedeo HIV Infection

Five-Week Literature

01 March 2021

22 February 2021

15 February 2021

08 February 2021

01 February 2021


01 February 2021

Multidisciplinary Journal Club

  1. Gao GF.
    From "A"IV to "Z"IKV: Attacks from Emerging and Re-emerging Pathogens.
    Cell. 2018;172:1157-1159.

  2. Harshfield EL, Pennells L, Schwartz JE, Willeit P, et al.
    Association Between Depressive Symptoms and Incident Cardiovascular Diseases.
    JAMA. 2020;324:2396-2405.

  3. Hu C, Hart SN, Gnanaolivu R, Huang H, et al.
    A Population-Based Study of Genes Previously Implicated in Breast Cancer.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa2005936.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016